Dulaglutide
A once-weekly GLP-1 injection sold as Trulicity. Known for its easy-to-use pen and milder GI side effects compared to semaglutide. Widely available in India.
Dulaglutide (Trulicity) is a weekly GLP-1 injection with a uniquely simple pen — no visible needle, no mixing, just push a button. It produces moderate weight loss and good blood sugar control, with somewhat milder GI side effects than semaglutide.
Good for you if: You have type 2 diabetes, are needle-averse (Trulicity's hidden-needle pen is the easiest to use), or want a weekly GLP-1 with a milder side-effect profile.
Dive deeper into the researchCommon side effects
- Nausea in 20–30% of users — generally milder than semaglutide
- Weight loss is moderate (3–5 kg) — less than semaglutide or tirzepatide
- Same class warnings for pancreatitis and thyroid apply
What does dulaglutide do?
Dulaglutide works the same way as semaglutide — it mimics GLP-1 to improve insulin response, reduce appetite, and slow gastric emptying. The weight loss is more moderate (about 3–5 kg at standard doses), but blood sugar control is strong, and GI side effects tend to be milder.
The REWIND trial showed dulaglutide reduces major cardiovascular events by 12% — even in people without established heart disease, making it one of the first GLP-1 drugs to show primary prevention benefit.
Who is it for?
- Adults with type 2 diabetes who need better blood sugar control
- People who are needle-averse — Trulicity's auto-pen has a hidden needle and requires just one button press
- Patients who want cardiovascular protection alongside diabetes management
- People who had intolerable GI side effects on semaglutide
How it's taken
Start at 0.75 mg/week, then increase to 1.5 mg after 4 weeks. Your doctor may increase further to 3.0 mg or 4.5 mg for additional benefit.
Single-use auto-pen — no visible needle. Press the pen against your skin, push the button, and hold for 5 seconds.
Availability in India
Trulicity is manufactured by Eli Lilly and is widely available in India. Cost is approximately ₹3,500–₹8,000 per month depending on dose — generally more affordable than Ozempic or Mounjaro.
Track your GLP-1 biomarkers with eterni
HbA1c, fasting insulin, body composition, and more — monitored over time so you can see if your protocol is working.
Get early accessFrequently Asked Questions
Is dulaglutide as effective as semaglutide?
For blood sugar control, both are effective. For weight loss, semaglutide produces significantly more (15–17% vs 3–5 kg). Dulaglutide has milder GI side effects and a more user-friendly pen. Your doctor can help decide based on your priorities.
Why would someone choose Trulicity over Ozempic?
Trulicity has a simpler pen (hidden needle, single button), milder GI side effects in many patients, and is often more affordable in India. It's a good choice if weight loss isn't the primary goal.
Does dulaglutide protect the heart?
Yes. The REWIND trial showed a 12% reduction in major cardiovascular events, including in people without established heart disease — making it one of the only GLP-1 drugs to show primary prevention benefit.
What are the side effects?
GI side effects (nausea, diarrhoea) are most common but tend to be milder than semaglutide. Serious risks — pancreatitis, gallbladder, thyroid — are the same across all GLP-1 drugs.
How it works in your body
Dulaglutide is a GLP-1 analogue attached to a modified IgG4 Fc fragment, which slows its clearance and allows weekly dosing. It activates GLP-1 receptors in the brain, pancreas, and gut — reducing appetite, improving insulin secretion, and slowing gastric emptying.
Clinical trial data
- REWIND: 12% reduction in major cardiovascular events over 5.4 years — including primary prevention
- AWARD programme: HbA1c reductions of 1.0–1.6% across multiple trials
- Weight loss: 3–5 kg at standard doses; up to 5–7 kg at 4.5 mg
- Safety: Well-established with years of post-marketing data
Biomarker monitoring
Same as other GLP-1 drugs: HbA1c, fasting glucose, fasting insulin, lipid panel, liver enzymes, kidney function, and thyroid panel every 3–6 months.
Side effects & safety
Dulaglutide generally has milder GI side effects than semaglutide, making it better tolerated for many patients.
- Nausea — 20–30% (less than semaglutide)
- Diarrhoea — 10–15%
- Vomiting — 8–12%
- Abdominal pain — 5–10%
- Decreased appetite — expected and therapeutic
- Pancreatitis — rare but serious
- Thyroid C-cell tumours — contraindicated with MTC/MEN 2 history
- Hypoglycaemia risk increases when combined with sulfonylureas or insulin
Know what's working. Know what's not.
eterni connects your lab results, medications, and retests — so you can see the trajectory, not just a snapshot.
Join the waitlist